How can survival be improved in localized osteosarcoma? (Q37782098)

23 August 2017

How can survival be improved in localized osteosarcoma? (English)

1 reference

23 August 2017

Dae-Geun Jeon

1

1 reference

PubMed ID

20735316

23 August 2017

Won Seok Song

series ordinal

2

1 reference

23 August 2017

1 August 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

8

1 reference

23 August 2017

1313-1325

1 reference

The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli

23 August 2017

1 reference

Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery

21 January 2018

1 reference

Progress in cancer management. Keynote address

21 January 2018

1 reference

Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

21 January 2018

1 reference

Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy

21 January 2018

1 reference

Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response

21 January 2018

1 reference

Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders.

21 January 2018

1 reference

Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup

21 January 2018

1 reference

Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials

21 January 2018

1 reference

High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study

21 January 2018

1 reference

Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

21 January 2018

1 reference

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

21 January 2018

1 reference

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

21 January 2018

1 reference

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma

21 January 2018

1 reference

Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma

21 January 2018

1 reference

Novel therapeutic agents for osteosarcoma

21 January 2018

1 reference

Chemotherapy resistance in osteosarcoma: current challenges and future directions.

21 January 2018

1 reference

Phase II Trial Of Pegylated-liposomal Doxorubicin (Doxil™) In Sarcoma*

21 January 2018

1 reference

Mechanisms of sarcoma development

21 January 2018

1 reference

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

21 January 2018

1 reference

Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.

21 January 2018

1 reference

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

21 January 2018

1 reference

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.

21 January 2018

1 reference

Critical role of notch signaling in osteosarcoma invasion and metastasis

21 January 2018

1 reference

Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma

21 January 2018

1 reference

Primary high-grade osteosarcoma: comparison between preadolescent and older patients.

21 January 2018

1 reference

Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute

21 January 2018

1 reference

Osteosarcoma developed in the period of maximal growth rate have inferior prognosis.

21 January 2018

1 reference

Primary osteosarcoma in patients older than 40 years of age.

21 January 2018

1 reference

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients

21 January 2018

1 reference

Osteosarcoma of the hand and forearm: experience of the Cooperative Osteosarcoma Study Group

21 January 2018

1 reference

Prognostic factors in localized extremity osteosarcoma: a systematic review

21 January 2018

1 reference

21 January 2018

Diaphyseal osteosarcoma

1 reference

Prognostic effect of diaphyseal location in osteosarcoma: a cohort case-control study at a single institute.

21 January 2018

1 reference

Initial tumor size predicts histologic response and survival in localized osteosarcoma patients

21 January 2018

1 reference

Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup

21 January 2018

1 reference

Delay in referral to a specialist soft-tissue sarcoma unit

21 January 2018

1 reference

Does length of symptoms before diagnosis of sarcoma affect patient survival?

21 January 2018

1 reference

Retrospective analysis of the impact of symptom duration on prognosis in soft tissue sarcoma.

21 January 2018

1 reference

Prognostic effect of inadvertent curettage without treatment delay in osteosarcoma

21 January 2018

1 reference

Prognostic effects of doctor-associated diagnostic delays in osteosarcoma

21 January 2018

1 reference

A review of clinical and molecular prognostic factors in osteosarcoma

21 January 2018

1 reference

Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma

21 January 2018

1 reference

The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.

21 January 2018

1 reference

Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography

21 January 2018

1 reference

Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity

21 January 2018

1 reference

Expression profiles of osteosarcoma that can predict response to chemotherapy.

21 January 2018

1 reference

Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma.

21 January 2018

1 reference

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

21 January 2018

1 reference

Resection of recurrent pulmonary metastases in patients with osteosarcoma

21 January 2018

1 reference

Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

21 January 2018

1 reference

Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999

21 January 2018

1 reference

Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution

21 January 2018

1 reference

Nonmetastatic osteosarcoma of the extremity with pathologic fracture at presentation: local and systemic control by amputation or limb salvage after preoperative chemotherapy

21 January 2018

1 reference

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor

21 January 2018

1 reference

Clinico-histologic parameters of osteosarcoma patients with late relapse

21 January 2018

1 reference

Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution

21 January 2018

1 reference

No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma

21 January 2018

1 reference

Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.79

1 reference

23 August 2017

1 reference

PubMed ID

20735316